ADVERTISEMENT
ADVERTISEMENT

Clinical Trial Misfortune

A human trial of a hepatitis C treatment is shut down after one of the participants died.

Cristina Luiggi

Nine patients had to be hospitalized and one eventually died after taking an experimental hepatitis C drug as part of a phase II clinical trial, resulting in the premature stoppage of the trial earlier this month (August 1). Although the cause of illness and death has not been confirmed, they could potentially be linked to the drug’s heart and kidney toxicity effects, Nature reported.

The drug, a polymerase inhibitor called BMS-986094that thwarts the viral replication machinery, was acquired earlier this year by Bristol-Myers Squibb. The company reportedly spent 1.8 billion in acquiring the drug’s original maker, Inhibitex, according to Nature. However, news of the clinical trial troubles has already caused a marked drop in the company’s shares.

There are currently several hepatitis C treatments available, including two new protease inhibitors—boceprevir and telaprevir—that were approved by the US Food and Drug Administration (FDA) last year. However, the...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT